Lion Biotechnologies Inc (NASDAQ: LBIO)

Lion Biotechnologies, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicate cancer cells. The company’s lead product includes LN-144, an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients tumors for the treatment of patients with refractory metastatic melanoma. It has a patent license agreement with the National Institutes of Health to develop, manufacture, and commercialize TIL therapies for the treatment of cervical, head and neck, bladder, lung, ovarian cancer, breast cancer, and colorectal cancers, as well as melanoma; cooperative research and development agreement with the National Institutes of Health and the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient’s tumor infiltrating lymphocytes; and manufacturing services agreement with Lonza Walkersville, Inc. to manufacture, package, ship, and perform quality assurance and quality control of TIL therapy.
Take a look at the 1-year chart of Lion (NASDAQ: LBIO) below with the added notations:

LBIO rallied off of its $5, November low making its way all the way up to a $15 high in March. In addition, over the last 6 months the $10 price level (blue) has become very important to the stock. Not only was $10 a key resistance in January and March, but that level has also been an important support since the end of March.

The Tale of the Tape: LBIO has a key level at $10. A trader could enter a long position on a break above $10 with a stop placed under the level. However, if traders are bearish on LBIO, a short trade could be made instead on a rally up to $10.
Please share this article

Stocks To Watch: FUEL, GOGO, GRPN, GEVO

Rocket Fuel Inc (NASDAQ:FUEL) The stock made an awesome move breaking out of a major resistance line (50EMA) with volume backed confirmation. I went long as its quite possible we should see a short term move near $10.5/share. The technical chart shows bullish sign with +DI line on top of -DI line and MACD rising. There could be good upside in FUEL so watch the stock closely on Friday.

Gogo Inc (NASDAQ:GOGO) broke through resistance at $23.10 accompanied with high volume. We should be able to see some decent upside movement for the bulls here. Next resistance lies at $25

Groupon Inc (NASDAQ:GRPN) is already at extremely oversold conditions with daily RSI (9) at 23. The MACD indicator has stabilized and volatility is dropping. On watch for a potential bounce.

Gevo, Inc. (NASDAQ:GEVO) Volume starts to pick up again (mainly in the final hour of trading). Could make a huge move to the upside. Keep it on your watch list. A break of $4 with force might give stock room to $4.36.

Please share this article

Is This The Chart That Scared Yellen Capital Out Of Biotechs? :IBB

Nope - no bubble here at all...
"wrong" or "early" or "other"... Biotechs driven by fun-durr-mentals like everything else.


As Bloomberg reports, perhaps there is a limit it this insanity...

Demand for options tied to declines in an exchange-traded fund tracking the companies rose to the highest level in three years relative to bullish ones, according to data compiled by Bloomberg. The Nasdaq Biotechnology Index has risen 549 percent since March 2009, including a 3.8 percent advance last week.

Interest in bearish options on drug developers has jumped in the last year after the group was called out as overvalued by Federal Reserve Chair Janet Yellen on two occasions. Biotechs are selling stock at a pace not seen in a decade and one concern is that something will disrupt the money spigot.

“The sector is dependent on capital that might shy away at the first sign of weakness,” Goldman Sachs derivatives strategists Katherine Fogertey and John Marshall wrote in a June 17 client note. “Recent pipeline setbacks have increased concern of this going forward.”

Biotech companies are doing follow-on stock offerings at the fastest pace in more than 10 years. In the first quarter, biotech and pharmaceutical companies used 93 share sales to reap $18.7 billion, three times more than in 2014, according to data compiled by Bloomberg.

*  *  *
Be careful...

“Biotech stocks have had a speculative fervor to them for some time now,” Todd Lowenstein, who helps manage $16 billion at HighMark Capital Management Inc. in Los Angeles, said by phone. “Of any part of the market, this is the one with the most bubble-like characteristics, without question.”

Or Buy buy buy...

“The customer base for biotech won’t stop buying,” Warren, who manages more than $100 million at Exton, Pennsylvania-based Warren, said by phone. “This sector is probably the best-placed to get any kind of growth, and it’s not going to go away quickly.”

Please share this article

Bill Barrett Corporation (NYSE: BBG)

Bill Barrett Corporation, an independent energy company, acquires, explores for, and develops oil and natural gas resources in the United States. It primarily holds interests in the Denver-Julesburg basin, the Uinta oil program in the Uinta Basin, and the Gibson Gulch area in the Piceance basin in the Rocky Mountain region of the United States. The company was founded in 2002 and is headquartered in Denver, Colorado.
Take a look at the 1-year chart of Barrett (NYSE: BBG) with the added notations:

Like most energy related stocks, BBG fell on hard times during the summer and fall. Even recently the stock tested its 52-week low. However, yesterday BBG actually broke back above the prior level of support at $8 (green). That break should mean higher prices for the stock in the short-term, at minimum.

The Tale of the Tape: BBG had a key level of support at $8 that it has now broke back above. A trader could enter a long position at $8 with a stop placed under the level. If the stock were to break below $8 a short position could be entered instead.
Please share this article